Eli Lilly v. Canada Eli Lilly and Company v. Canada (ICSID Case No. UNCT/14/2)
United States of America
Patents for two pharmaceutical products, Strattera and Zyprexa.
Claims arising out of the invalidation of the claimant's Strattera and Zyprexa pharmaceutical patents by Canada.
Secondary: C - Manufacturing
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
ICSID (International Centre for Settlement of Investment Disputes)
van den Berg, A. J.
Born, G. B.
Bethlehem, D.
Decided in favour of State
500.00 mln CAD (483.40 mln USD)
Data not available
Indirect expropriation

Fair and equitable treatment/Minimum standard of treatment, including denial of justice claims
None - all claims dismissed at the merits stage